CD274 and adenocarcinoma: During the years 2017–2018, most patients with adenocarcinoma or squamous cell carcinoma with no actionable mutations and PD-L1 TPS ≥50% received PD-1/PD-L1 inhibitor monotherapy (96.8% and 91.3% respectively; Tables 2A, B).